Compare VABK & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | CNTN |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.3M | 185.3M |
| IPO Year | 2013 | 2022 |
| Metric | VABK | CNTN |
|---|---|---|
| Price | $44.42 | $3.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.7K | ★ 898.0K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 12.70 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $45.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.60 | $2.14 |
| 52 Week High | $48.58 | $5.27 |
| Indicator | VABK | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 53.34 |
| Support Level | $37.96 | $3.04 |
| Resistance Level | $48.58 | $3.82 |
| Average True Range (ATR) | 0.79 | 0.36 |
| MACD | 0.10 | 0.09 |
| Stochastic Oscillator | 81.85 | 66.26 |
Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.